Data:
{
"symbol": "TCRX",
"price": 0.3752,
"marketCap": 22915051,
"beta": 1.072,
"lastDividend": 0,
"range": "0.3506-2.57",
"change": -0.0059,
"changePercentage": -1.54815,
"volume": 2432225,
"averageVolume": 697057,
"companyName": "TScan Therapeutics, Inc.",
"currency": "USD",
"cik": "0001783328",
"isin": "US89854M1018",
"cusip": "89854M101",
"exchangeFullName": "NASDAQ",
"exchange": "NASDAQ",
"industry": "Biotechnology",
"website": "https://www.tscan.com",
"description": "TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company\u2019s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn\u2019s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.",
"ceo": "Gavin MacBeath",
"sector": "Healthcare",
"country": "US",
"fullTimeEmployees": "138",
"phone": "857 399 9500",
"address": "830 Winter Street",
"city": "Waltham",
"state": "MA",
"zip": "02451",
"image": "https://images.financialmodelingprep.com/symbol/TCRX.png",
"ipoDate": "2021-07-16",
"defaultImage": false,
"isEtf": false,
"isActivelyTrading": true,
"isAdr": false,
"isFund": false
}
Data:
{
"symbol": "TCRX",
"name": "TScan Therapeutics, Inc.",
"price": 0.3752,
"changePercentage": -1.54815,
"change": -0.0059,
"volume": 2432225,
"dayLow": 0.3506,
"dayHigh": 0.4023,
"yearHigh": 2.57,
"yearLow": 0.3506,
"marketCap": 22915051,
"priceAvg50": 0.84852,
"priceAvg200": 1.00589,
"exchange": "NASDAQ",
"open": 0.3811,
"previousClose": 0.3811,
"timestamp": 1788459899,
"chart_vwap_daily": [
{
"t": "2026-07-24",
"v": 0.8169,
"c": 0.794
},
{
"t": "2026-07-27",
"v": 0.7919,
"c": 0.7683
},
{
"t": "2026-07-28",
"v": 0.7553,
"c": 0.774
},
{
"t": "2026-07-29",
"v": 0.7525,
"c": 0.7416
},
{
"t": "2026-07-30",
"v": 0.763,
"c": 0.7557
},
{
"t": "2026-07-31",
"v": 0.7491,
"c": 0.743
},
{
"t": "2026-08-03",
"v": 0.7314,
"c": 0.7234
},
{
"t": "2026-08-04",
"v": 0.738,
"c": 0.7365
},
{
"t": "2026-08-05",
"v": 0.7654,
"c": 0.78
},
{
"t": "2026-08-06",
"v": 0.7688,
"c": 0.7632
},
{
"t": "2026-08-07",
"v": 0.784,
"c": 0.7962
},
{
"t": "2026-08-10",
"v": 0.7715,
"c": 0.767
},
{
"t": "2026-08-11",
"v": 0.7721,
"c": 0.7768
},
{
"t": "2026-08-12",
"v": 0.7633,
"c": 0.773
},
{
"t": "2026-08-13",
"v": 0.7752,
"c": 0.772
},
{
"t": "2026-08-14",
"v": 0.7596,
"c": 0.7788
},
{
"t": "2026-08-17",
"v": 0.7738,
"c": 0.7835
},
{
"t": "2026-08-18",
"v": 0.7998,
"c": 0.8247
},
{
"t": "2026-08-19",
"v": 0.7847,
"c": 0.75
},
{
"t": "2026-08-20",
"v": 0.7616,
"c": 0.7762
},
{
"t": "2026-08-21",
"v": 0.7808,
"c": 0.7795
},
{
"t": "2026-08-24",
"v": 0.7823,
"c": 0.7993
},
{
"t": "2026-08-25",
"v": 0.797,
"c": 0.7937
},
{
"t": "2026-08-26",
"v": 0.7788,
"c": 0.7774
},
{
"t": "2026-08-27",
"v": 0.7567,
"c": 0.7502
},
{
"t": "2026-08-28",
"v": 0.7519,
"c": 0.7535
},
{
"t": "2026-08-31",
"v": 0.7383,
"c": 0.7297
},
{
"t": "2026-09-01",
"v": 0.673,
"c": 0.6663
},
{
"t": "2026-09-02",
"v": 0.4121,
"c": 0.3811
},
{
"t": "2026-09-03",
"v": 0.3725,
"c": 0.3752
}
],
"vwap_summary": {
"days": 30,
"days_above": 12,
"days_below": 18,
"pct_days_above": 40,
"position": "above",
"gap_pct": 0.72,
"streak_days": 1
}
}
Data:
{
"volume": 2432225,
"avgVolume": 697057,
"short_ratio": [
{
"symbol": "TCRX",
"file_date": "2026-09-02",
"date": "20260902",
"short_volume": 3520223,
"short_exempt_volume": 726706,
"total_volume": 5971886,
"short_volume_ratio": 0.5895,
"signal": "Bearish"
}
],
"volume_profile": {
"poc": 0.38,
"vah": 0.7,
"val": 0.35,
"profile": [
{
"price": 0.36,
"volume": 879710
},
{
"price": 0.37,
"volume": 1726484
},
{
"price": 0.37,
"volume": 1190152
},
{
"price": 0.38,
"volume": 1745488
},
{
"price": 0.39,
"volume": 539540
},
{
"price": 0.4,
"volume": 693147
},
{
"price": 0.41,
"volume": 374662
},
{
"price": 0.41,
"volume": 0
},
{
"price": 0.42,
"volume": 826820
},
{
"price": 0.43,
"volume": 278341
},
{
"price": 0.44,
"volume": 148243
},
{
"price": 0.45,
"volume": 182833
},
{
"price": 0.45,
"volume": 91752
},
{
"price": 0.46,
"volume": 822427
},
{
"price": 0.47,
"volume": 135777
},
{
"price": 0.48,
"volume": 334816
},
{
"price": 0.49,
"volume": 151329
},
{
"price": 0.49,
"volume": 0
},
{
"price": 0.5,
"volume": 0
},
{
"price": 0.51,
"volume": 0
},
{
"price": 0.52,
"volume": 211889
},
{
"price": 0.53,
"volume": 0
},
{
"price": 0.53,
"volume": 0
},
{
"price": 0.54,
"volume": 0
},
{
"price": 0.55,
"volume": 0
},
{
"price": 0.56,
"volume": 0
},
{
"price": 0.57,
"volume": 0
},
{
"price": 0.57,
"volume": 0
},
{
"price": 0.58,
"volume": 0
},
{
"price": 0.59,
"volume": 0
},
{
"price": 0.6,
"volume": 0
},
{
"price": 0.61,
"volume": 0
},
{
"price": 0.61,
"volume": 0
},
{
"price": 0.62,
"volume": 0
},
{
"price": 0.63,
"volume": 0
},
{
"price": 0.64,
"volume": 0
},
{
"price": 0.65,
"volume": 0
},
{
"price": 0.65,
"volume": 0
},
{
"price": 0.66,
"volume": 84538
},
{
"price": 0.67,
"volume": 559087
},
{
"price": 0.68,
"volume": 64329
},
{
"price": 0.69,
"volume": 0
},
{
"price": 0.69,
"volume": 57221
},
{
"price": 0.7,
"volume": 0
},
{
"price": 0.71,
"volume": 19823
},
{
"price": 0.72,
"volume": 0
},
{
"price": 0.72,
"volume": 104563
},
{
"price": 0.73,
"volume": 110789
},
{
"price": 0.74,
"volume": 3117
},
{
"price": 0.75,
"volume": 399523
},
{
"price": 0.76,
"volume": 669400
},
{
"price": 0.76,
"volume": 586911
},
{
"price": 0.77,
"volume": 1297104
},
{
"price": 0.78,
"volume": 668004
},
{
"price": 0.79,
"volume": 335691
},
{
"price": 0.8,
"volume": 192941
},
{
"price": 0.8,
"volume": 105911
},
{
"price": 0.81,
"volume": 134034
},
{
"price": 0.82,
"volume": 39366
},
{
"price": 0.83,
"volume": 14726
}
],
"sessions": 20
}
}
Data:
{
"symbol": "TCRX",
"marketCap": 22915051,
"enterpriseValueTTM": 13652051,
"evToSalesTTM": 1.9198496695260865,
"evToOperatingCashFlowTTM": -0.11740669934640521,
"evToFreeCashFlowTTM": -0.11526651694121023,
"evToEBITDATTM": -0.12184870716969681,
"netDebtToEBITDATTM": 0.08267509215376515,
"currentRatioTTM": 3.371754295310683,
"incomeQualityTTM": 0.987834715237189,
"grahamNumberTTM": null,
"grahamNetNetTTM": -0.01752227518270685,
"taxBurdenTTM": 1,
"interestBurdenTTM": 1.0242684232051025,
"workingCapitalTTM": 73439000,
"investedCapitalTTM": 135410000,
"returnOnAssetsTTM": -0.686559503534517,
"operatingReturnOnAssetsTTM": -0.6455710777816159,
"returnOnTangibleAssetsTTM": -0.686559503534517,
"returnOnEquityTTM": -1.087195354260711,
"returnOnInvestedCapitalTTM": -0.7538020911501325,
"returnOnCapitalEmployedTTM": -0.8580234610785262,
"earningsYieldTTM": -2.4142674266382054,
"freeCashFlowYieldTTM": -5.16861166924743,
"capexToOperatingCashFlowTTM": -0.018567251461988305,
"capexToDepreciationTTM": 0.7491325468424705,
"capexToRevenueTTM": 0.3036141189706089,
"salesGeneralAndAdministrativeToRevenueTTM": 4.188862325973844,
"researchAndDevelopementToRevenueTTM": 13.645619462804106,
"stockBasedCompensationToRevenueTTM": 1.3839122486288848,
"intangiblesToTotalAssetsTTM": 0,
"averageReceivablesTTM": 0,
"averagePayablesTTM": 2712500,
"averageInventoryTTM": 0,
"daysOfSalesOutstandingTTM": 0,
"daysOfPayablesOutstandingTTM": 1644.3434343434344,
"daysOfInventoryOutstandingTTM": 0,
"operatingCycleTTM": 0,
"cashConversionCycleTTM": -1644.3434343434344,
"freeCashFlowToEquityTTM": -118439000,
"freeCashFlowToFirmTTM": -115650000,
"tangibleAssetValueTTM": 69019000,
"netCurrentAssetValueTTM": 1970000,
"grossProfitMarginTTM": 0.9025453522711292,
"ebitMarginTTM": -16.16129939530305,
"ebitdaMarginTTM": -15.756011812684573,
"operatingProfitMarginTTM": -16.951483616931515,
"pretaxProfitMarginTTM": -16.553508648572635,
"continuousOperationsProfitMarginTTM": -16.553508648572635,
"netProfitMarginTTM": -16.553508648572635,
"bottomLineProfitMarginTTM": -16.553508648572635,
"receivablesTurnoverTTM": 0,
"payablesTurnoverTTM": 0.2219730941704036,
"inventoryTurnoverTTM": 0,
"fixedAssetTurnoverTTM": 0.11474722047409272,
"assetTurnoverTTM": 0.041475165060775025,
"quickRatioTTM": 3.371754295310683,
"solvencyRatioTTM": -1.1210254507824626,
"cashRatioTTM": 3.234595013564139,
"priceToEarningsRatioTTM": -0.4123076923076922,
"priceToEarningsGrowthRatioTTM": -0.0231558658449497,
"forwardPriceToEarningsGrowthRatioTTM": 0.03551166253101734,
"priceToEarningsDilutedRatioTTM": -0.4123076923076922,
"priceToEarningsDilutedGrowthRatioTTM": -0.0231558658449497,
"priceToBookRatioTTM": 0.7064260424752603,
"priceToSalesRatioTTM": 3.222479398115596,
"priceToFreeCashFlowRatioTTM": -0.19347555281621762,
"priceToOperatingCashFlowRatioTTM": -0.4193052891778466,
"debtToAssetsRatioTTM": 0.5301367146489979,
"debtToEquityRatioTTM": 1.316927222938611,
"debtToCapitalRatioTTM": 0.5683938666266447,
"longTermDebtToCapitalRatioTTM": 0.2338968376419398,
"financialLeverageRatioTTM": 2.484127559077935,
"workingCapitalTurnoverRatioTTM": 0.07636588181598518,
"operatingCashFlowRatioTTM": -3.755328768892908,
"operatingCashFlowSalesRatioTTM": -16.352130502039095,
"freeCashFlowOperatingCashFlowRatioTTM": 1.0185672514619883,
"debtServiceCoverageRatioTTM": -7.729097682119205,
"interestCoverageRatioTTM": -43.22050914306203,
"shortTermOperatingCashFlowCoverageRatioTTM": -9.932519005723071,
"operatingCashFlowCoverageRatioTTM": -1.2793064372393914,
"capitalExpenditureCoverageRatioTTM": -53.85826771653543,
"dividendPaidAndCapexCoverageRatioTTM": -53.85826771653543,
"dividendPayoutRatioTTM": 0,
"dividendYieldTTM": 0,
"revenuePerShareTTM": 0.054721519026889945,
"netIncomePerShareTTM": -0.9058331384746546,
"interestDebtPerShareTTM": 0.7209142659931238,
"cashPerShareTTM": 0.7707338573558135,
"bookValuePerShareTTM": 0.5311242471828037,
"tangibleBookValuePerShareTTM": 0.5311242471828037,
"shareholdersEquityPerShareTTM": 0.5311242471828037,
"operatingCashFlowPerShareTTM": -0.8948134203975197,
"capexPerShareTTM": 0.016614225788082602,
"freeCashFlowPerShareTTM": -0.9114276461856023,
"netIncomePerEBTTTM": 1,
"ebtPerEbitTTM": 0.9765227057788987,
"priceToFairValueTTM": 0.7064260424752603,
"debtToMarketCapTTM": 1.4304572134707447,
"effectiveTaxRateTTM": 0,
"enterpriseValueMultipleTTM": -0.12184870716969681,
"dividendPerShareTTM": 0,
"revenue_history": [
{
"date": "2025",
"revenue": 10325000
}
],
"dcf": {
"symbol": "TCRX",
"date": "2026-09-03",
"dcf": -4.932054514177959,
"Stock Price": 0.3664
},
"statements": {
"income": [
{
"date": "2025-12-31",
"symbol": "TCRX",
"reportedCurrency": "USD",
"cik": "0001783328",
"filingDate": "2026-03-04",
"acceptedDate": "2026-03-04 07:30:55",
"fiscalYear": "2025",
"period": "FY",
"revenue": 10325000,
"costOfRevenue": 2866000,
"grossProfit": 7459000,
"researchAndDevelopmentExpenses": 114150000,
"generalAndAdministrativeExpenses": 31988000,
"sellingAndMarketingExpenses": 0,
"sellingGeneralAndAdministrativeExpenses": 31988000,
"otherExpenses": -2866000,
"operatingExpenses": 143272000,
"costAndExpenses": 146138000,
"netInterestIncome": 6047000,
"interestIncome": 8816000,
"interestExpense": 2769000,
"depreciationAndAmortization": 2866000,
"ebitda": -124131000,
"ebit": -126997000,
"nonOperatingIncomeExcludingInterest": -8816000,
"operatingIncome": -135813000,
"totalOtherIncomeExpensesNet": 6047000,
"incomeBeforeTax": -129766000,
"incomeTaxExpense": 0,
"netIncomeFromContinuingOperations": -129766000,
"netIncomeFromDiscontinuedOperations": 0,
"otherAdjustmentsToNetIncome": 0,
"netIncome": -129766000,
"netIncomeDeductions": 0,
"bottomLineNetIncome": -129766000,
"eps": -1,
"epsDiluted": -1,
"weightedAverageShsOut": 129862038,
"weightedAverageShsOutDil": 129862038
}
],
"balance_sheet": [
{
"date": "2025-12-31",
"symbol": "TCRX",
"reportedCurrency": "USD",
"cik": "0001783328",
"filingDate": "2026-03-04",
"acceptedDate": "2026-03-04 07:30:55",
"fiscalYear": "2025",
"period": "FY",
"cashAndCashEquivalents": 152406000,
"shortTermInvestments": 0,
"cashAndShortTermInvestments": 152406000,
"netReceivables": 0,
"accountsReceivables": 0,
"otherReceivables": 0,
"inventory": 0,
"prepaids": 0,
"otherCurrentAssets": 4802000,
"totalCurrentAssets": 157208000,
"propertyPlantEquipmentNet": 66449000,
"goodwill": 0,
"intangibleAssets": 0,
"goodwillAndIntangibleAssets": 0,
"longTermInvestments": 5031000,
"taxAssets": 15775000,
"otherNonCurrentAssets": -15674000,
"totalNonCurrentAssets": 71581000,
"otherAssets": 0,
"totalAssets": 228789000,
"totalPayables": 1241000,
"accountPayables": 1241000,
"otherPayables": 0,
"accruedExpenses": 3327000,
"shortTermDebt": 0,
"capitalLeaseObligationsCurrent": 7167000,
"taxPayables": 0,
"deferredRevenue": 2619000,
"otherCurrentLiabilities": 4341000,
"totalCurrentLiabilities": 18695000,
"longTermDebt": 32534000,
"capitalLeaseObligationsNonCurrent": 54437000,
"deferredRevenueNonCurrent": 0,
"deferredTaxLiabilitiesNonCurrent": 0,
"otherNonCurrentLiabilities": 0,
"totalNonCurrentLiabilities": 86971000,
"otherLiabilities": 0,
"capitalLeaseObligations": 61604000,
"totalLiabilities": 105666000,
"treasuryStock": 0,
"preferredStock": 0,
"commonStock": 5000,
"retainedEarnings": -504862000,
"additionalPaidInCapital": 627979000,
"accumulatedOtherComprehensiveIncomeLoss": 0,
"otherTotalStockholdersEquity": 0,
"totalStockholdersEquity": 123123000,
"totalEquity": 123123000,
"minorityInterest": 0,
"totalLiabilitiesAndTotalEquity": 228789000,
"totalInvestments": 5031000,
"totalDebt": 94138000,
"netDebt": -58268000
}
],
"cash_flow": [
{
"date": "2025-12-31",
"symbol": "TCRX",
"reportedCurrency": "USD",
"cik": "0001783328",
"filingDate": "2026-03-04",
"acceptedDate": "2026-03-04 07:30:55",
"fiscalYear": "2025",
"period": "FY",
"netIncome": -129766000,
"depreciationAndAmortization": 2866000,
"deferredIncomeTax": 0,
"stockBasedCompensation": 11706000,
"changeInWorkingCapital": -18178000,
"accountsReceivables": 0,
"inventory": 0,
"accountsPayables": -3011000,
"otherWorkingCapital": -15167000,
"otherNonCashItems": -1947000,
"netCashProvidedByOperatingActivities": -135319000,
"investmentsInPropertyPlantAndEquipment": -4407000,
"acquisitionsNet": 0,
"purchasesOfInvestments": -87471000,
"salesMaturitiesOfInvestments": 201250000,
"otherInvestingActivities": 0,
"netCashProvidedByInvestingActivities": 109372000,
"netDebtIssuance": 0,
"longTermNetDebtIssuance": 0,
"shortTermNetDebtIssuance": 0,
"netStockIssuance": 264000,
"netCommonStockIssuance": 264000,
"commonStockIssuance": 264000,
"commonStockRepurchased": 0,
"netPreferredStockIssuance": 0,
"netDividendsPaid": 0,
"commonDividendsPaid": 0,
"preferredDividendsPaid": 0,
"otherFinancingActivities": -600000,
"netCashProvidedByFinancingActivities": -336000,
"effectOfForexChangesOnCash": 0,
"netChangeInCash": -26283000,
"cashAtEndOfPeriod": 157437000,
"cashAtBeginningOfPeriod": 183720000,
"operatingCashFlow": -135319000,
"capitalExpenditure": -4407000,
"freeCashFlow": -139726000,
"incomeTaxesPaid": 0,
"interestPaid": 0
}
]
}
}
Data:
{
"price": 0.3752,
"rsi": 17.401215925876272,
"sma20": 0.7302049999999995,
"sma50": 0.8383559999999909,
"sma200": 1.002194500000001,
"adx": 21.670230817404832,
"atr": 0.07,
"atr_pct": 18.66,
"atr_expansion_pct": 46.6,
"di_plus": 7.8,
"di_minus": 49.0,
"high_52w": 2.52,
"low_52w": 0.3752,
"structure": {
"ema8": 0.5973437585977204,
"ema21": 0.7043763305760897,
"ema50": 0.8043068050876144,
"ema200": 1.1145936237027843,
"ema10": 0.625147172456703,
"ema20": 0.6993933909746469,
"ema10_slope_pct": -19.6,
"ema20_slope_pct": -11.54,
"trend_dir": "down",
"checks": {
"price_above_all": false,
"ema_stacked": false,
"ema21_rising": false,
"ema50_rising": false,
"adx_over_30": false,
"higher_highs_lows": false,
"lower_highs_lows": true,
"near_21ema": false
},
"dist_21ema_pct": -46.7,
"_no_bars": false,
"macd": {
"macd": -0.081,
"signal": -0.045,
"histogram": -0.036
},
"bollinger": {
"mid": 0.73,
"upper": 0.97,
"lower": 0.49,
"width_pct": 66.47
},
"crossover": {
"fresh_cross": null,
"pre_compressed": null,
"held_above_21": null,
"candles_since": null,
"intraday_support": false
},
"momentum": {
"roc10": -51.7,
"ret_3d": -48.58,
"ret_5d": -49.99,
"roc10_accel": -48.84,
"checks": {
"roc_over_5": false,
"rsi_in_band": false,
"macd_expanding": false,
"top_quartile_3d": false,
"no_big_down": false,
"near_high": false
},
"volume": {
"rvol": 2.91,
"checks": {
"rvol_over_2": true,
"up_vol_beats_down": false,
"obv_new_high": false,
"surge_day": true,
"pullback_declining_vol": false,
"last_up_beats_down": false
}
}
},
"relative_strength": {
"sector": "Healthcare",
"sector_etf": "XLV",
"sector_etf_ret10d": -1.55,
"checks": {
"beats_spy_all": false,
"beats_sector_10d": false,
"rs_line_at_high": false,
"sector_top3": true
}
},
"commodity": {},
"universe": {
"checks": {
"price_over_20": false,
"avg_vol_over_2m": false,
"mcap_over_1b": false,
"no_earnings_7d": true,
"not_lev_etf_spac": true,
"bidask_spread": null,
"dollar_vol_over_10m": false
},
"avg_dollar_vol": 261535.78639999998,
"avg_vol": 697057
},
"options": {}
}
}
Data:
{
"prior_day": {
"high": 0.4,
"low": 0.35,
"close": 0.38,
"date": "2026-09-03"
},
"woodie_pivots": {
"PP": 0.38,
"R1": 0.4,
"S1": 0.35,
"R2": 0.43,
"S2": 0.32
},
"swing": {
"high_20d": 0.84,
"low_20d": 0.35,
"high_60d": 1.28,
"low_60d": 0.35
},
"orb": {
"high": 0.38,
"low": 0.35,
"date": "2026-09-03"
},
"vwap": 0.37,
"volume_profile": {
"poc": 0.38,
"vah": 0.7,
"val": 0.35,
"sessions": 20
},
"premarket": {
"date": "2026-09-03",
"high": 0.39,
"low": 0.35,
"last": 0.39,
"volume": 103061,
"gap_pct": 2.28,
"path": "04:00 0.36 -> 06:00 0.36 -> 07:10 0.36 -> 08:30 0.37 -> 09:25 0.39",
"bars": 29,
"last_bar_et": "09:25"
},
"recent_daily": [
{
"d": "2026-07-31",
"o": 0.78,
"h": 0.78,
"l": 0.7301,
"c": 0.743,
"v": 253902.341611
},
{
"d": "2026-08-03",
"o": 0.7591,
"h": 0.7798,
"l": 0.7201,
"c": 0.7234,
"v": 441443.181024
},
{
"d": "2026-08-04",
"o": 0.716,
"h": 0.7575,
"l": 0.716,
"c": 0.7365,
"v": 796346.540961
},
{
"d": "2026-08-05",
"o": 0.7448,
"h": 0.78,
"l": 0.7448,
"c": 0.78,
"v": 298715.9345
},
{
"d": "2026-08-06",
"o": 0.7709,
"h": 0.7809,
"l": 0.75,
"c": 0.7632,
"v": 129861.4207
},
{
"d": "2026-08-07",
"o": 0.7542,
"h": 0.8041,
"l": 0.7542,
"c": 0.7962,
"v": 336330.5155
},
{
"d": "2026-08-10",
"o": 0.7999,
"h": 0.7999,
"l": 0.7624,
"c": 0.767,
"v": 464266.678101
},
{
"d": "2026-08-11",
"o": 0.7719,
"h": 0.7988,
"l": 0.7636,
"c": 0.7768,
"v": 248094.4525
},
{
"d": "2026-08-12",
"o": 0.791,
"h": 0.791,
"l": 0.7512,
"c": 0.773,
"v": 527968.7032
},
{
"d": "2026-08-13",
"o": 0.7789,
"h": 0.79,
"l": 0.764,
"c": 0.772,
"v": 297631.1855
},
{
"d": "2026-08-14",
"o": 0.768,
"h": 0.789,
"l": 0.741,
"c": 0.7788,
"v": 278415.5155
},
{
"d": "2026-08-17",
"o": 0.78,
"h": 0.795,
"l": 0.7625,
"c": 0.7835,
"v": 352780.5155
},
{
"d": "2026-08-18",
"o": 0.77,
"h": 0.838,
"l": 0.77,
"c": 0.8247,
"v": 173483.3135
},
{
"d": "2026-08-19",
"o": 0.77,
"h": 0.8246,
"l": 0.75,
"c": 0.75,
"v": 580133.5155
},
{
"d": "2026-08-20",
"o": 0.75,
"h": 0.7886,
"l": 0.75,
"c": 0.7762,
"v": 338261.318241
},
{
"d": "2026-08-21",
"o": 0.79,
"h": 0.79,
"l": 0.7718,
"c": 0.7795,
"v": 136157.1007
},
{
"d": "2026-08-24",
"o": 0.79,
"h": 0.7999,
"l": 0.7682,
"c": 0.7993,
"v": 194411.6987
},
{
"d": "2026-08-25",
"o": 0.7924,
"h": 0.8111,
"l": 0.7774,
"c": 0.7937,
"v": 180597.0106
},
{
"d": "2026-08-26",
"o": 0.7776,
"h": 0.7917,
"l": 0.7738,
"c": 0.7774,
"v": 68396.237
},
{
"d": "2026-08-27",
"o": 0.7773,
"h": 0.8,
"l": 0.7474,
"c": 0.7502,
"v": 288103.0106
},
{
"d": "2026-08-28",
"o": 0.7551,
"h": 0.78,
"l": 0.7499,
"c": 0.7535,
"v": 150791.617272
},
{
"d": "2026-08-31",
"o": 0.75,
"h": 0.7657,
"l": 0.7209,
"c": 0.7297,
"v": 330387.0106
},
{
"d": "2026-09-01",
"o": 0.7226,
"h": 0.7699,
"l": 0.6556,
"c": 0.6663,
"v": 820279.0106
},
{
"d": "2026-09-02",
"o": 0.55,
"h": 0.57,
"l": 0.36,
"c": 0.3811,
"v": 8517352.350918
},
{
"d": "2026-09-03",
"o": 0.3811,
"h": 0.4023,
"l": 0.3506,
"c": 0.3752,
"v": 2432225.211921
}
]
}
Data:
{
"estimates": [
{
"symbol": "TCRX",
"date": "2030-12-31",
"revenueLow": 36908702,
"revenueHigh": 122145659,
"revenueAvg": 78697667,
"ebitdaLow": -73713674,
"ebitdaHigh": 1863435,
"ebitdaAvg": -35190100,
"ebitLow": -88805783,
"ebitHigh": -13228673,
"ebitAvg": -50282209,
"netIncomeLow": -92199450,
"netIncomeHigh": -16622340,
"netIncomeAvg": -53675876,
"sgaExpenseLow": 130459159,
"sgaExpenseHigh": 431741544,
"sgaExpenseAvg": 278168316,
"epsAvg": -0.41333,
"epsHigh": -0.128,
"epsLow": -0.70998,
"numAnalystsRevenue": 2,
"numAnalystsEps": 1
},
{
"symbol": "TCRX",
"date": "2029-12-31",
"revenueLow": 14946357,
"revenueHigh": 49463474,
"revenueAvg": 31869000,
"ebitdaLow": -154098213,
"ebitdaHigh": -18789760,
"ebitdaAvg": -85127185,
"ebitLow": -161675269,
"ebitHigh": -26366816,
"ebitAvg": -92704241,
"netIncomeLow": -165068936,
"netIncomeHigh": -29760483,
"netIncomeAvg": -96097908,
"sgaExpenseLow": 52830066,
"sgaExpenseHigh": 174835821,
"sgaExpenseAvg": 112645601,
"epsAvg": -0.74,
"epsHigh": -0.22917,
"epsLow": -1.27111,
"numAnalystsRevenue": 2,
"numAnalystsEps": 1
},
{
"symbol": "TCRX",
"date": "2028-12-31",
"revenueLow": 9729713,
"revenueHigh": 32199512,
"revenueAvg": 20745940,
"ebitdaLow": -115550408,
"ebitdaHigh": -75063320,
"ebitdaAvg": -95306864,
"ebitLow": -120450565,
"ebitHigh": -79963477,
"ebitAvg": -100207021,
"netIncomeLow": -123844232,
"netIncomeHigh": -83357144,
"netIncomeAvg": -103600688,
"sgaExpenseLow": 34391081,
"sgaExpenseHigh": 113813844,
"sgaExpenseAvg": 73329533,
"epsAvg": -0.81,
"epsHigh": -0.64189,
"epsLow": -0.95366,
"numAnalystsRevenue": 4,
"numAnalystsEps": 3
},
{
"symbol": "TCRX",
"date": "2027-12-31",
"revenueLow": 5030947,
"revenueHigh": 7984962,
"revenueAvg": 6511463,
"ebitdaLow": -131824855,
"ebitdaHigh": -101481291,
"ebitdaAvg": -125717503,
"ebitLow": -134974335,
"ebitHigh": -104630771,
"ebitAvg": -128866983,
"netIncomeLow": -138368002,
"netIncomeHigh": -108024438,
"netIncomeAvg": -132260650,
"sgaExpenseLow": 17782611,
"sgaExpenseHigh": 28224006,
"sgaExpenseAvg": 23015710,
"epsAvg": -0.944,
"epsHigh": -0.83184,
"epsLow": -1.0655,
"numAnalystsRevenue": 4,
"numAnalystsEps": 4
}
],
"price_target": {
"symbol": "TCRX",
"targetHigh": 1,
"targetLow": 1,
"targetConsensus": 1,
"targetMedian": 1
},
"ratings": {
"symbol": "TCRX",
"rating": "C+",
"overallScore": 2,
"discountedCashFlowScore": 5,
"returnOnEquityScore": 1,
"returnOnAssetsScore": 1,
"debtToEquityScore": 1,
"priceToEarningsScore": 1,
"priceToBookScore": 3
},
"grades": [
{
"symbol": "TCRX",
"date": "2026-09-03",
"gradingCompany": "Wedbush",
"previousGrade": "Outperform",
"newGrade": "Neutral",
"action": "downgrade"
},
{
"symbol": "TCRX",
"date": "2026-09-02",
"gradingCompany": "Needham",
"previousGrade": "Buy",
"newGrade": "Hold",
"action": "downgrade"
},
{
"symbol": "TCRX",
"date": "2026-08-12",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "TCRX",
"date": "2026-06-23",
"gradingCompany": "Wedbush",
"previousGrade": "Outperform",
"newGrade": "Outperform",
"action": "maintain"
},
{
"symbol": "TCRX",
"date": "2026-06-23",
"gradingCompany": "Needham",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "TCRX",
"date": "2026-03-05",
"gradingCompany": "Wedbush",
"previousGrade": "Outperform",
"newGrade": "Outperform",
"action": "maintain"
},
{
"symbol": "TCRX",
"date": "2025-11-13",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "TCRX",
"date": "2025-11-04",
"gradingCompany": "BTIG",
"previousGrade": "Buy",
"newGrade": "Neutral",
"action": "downgrade"
},
{
"symbol": "TCRX",
"date": "2025-11-04",
"gradingCompany": "Needham",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
}
]
}
Data:
[
{
"title": "Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1",
"url": "https://www.benzinga.com/news/26/09/61600985/wedbush-downgrades-tscan-therapeutics-neutral-lowers-price-target-1",
"source": "benzinga",
"date": "2026-09-03T13:09:08.424000+00:00",
"summary": "Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.",
"image": ""
},
{
"title": "U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.56% By Investing.com",
"url": "https://www.investing.com/news/stock-market-news/us-stocks-higher-at-close-of-trade-dow-jones-industrial-average-up-056-4886746",
"source": "Investing.com",
"date": "2026-09-02T20:30:59Z",
"summary": "Investing.com - U.S. stocks were higher after the close on Wednesday, as gains in the Basic Materials, Healthcare and Financials sectors led shares higher.\n\nAt the close in NYSE, the Dow Jones Industrial Average added 0.56%, while the S&P 500 index added 0.46%, and the NASDAQ Com",
"image": "https://content-media.investing.com/news/LYNXMPEM1P118_1200_L.jpg"
},
{
"title": "Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift By Investing.com",
"url": "https://www.investing.com/news/analyst-ratings/tscan-therapeutics-stock-rating-cut-to-neutral-by-wedbush-on-strategy-shift-93CH-4886478",
"source": "Investing.com",
"date": "2026-09-02T15:04:56Z",
"summary": "Investing.com - Wedbush downgraded Tscan Therapeutics Inc (NASDAQ:TCRX) to Neutral from Outperform on Tuesday and lowered its price target to $1.00 from $5.00 following the company's strategic reorganization announced that morning. The stock fell 14% over the past week to $0.42, ",
"image": "https://content-media.investing.com/news/moved_LYNXMPEM3S10Z_1200_L.jpg"
},
{
"title": "TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program",
"url": "https://finance.yahoo.com/healthcare/articles/tscan-therapeutics-cuts-workforce-75-123041433.html",
"source": "Yahoo! Finance",
"date": "2026-09-02T12:30:41Z",
"summary": "TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor, or TCR-T, program targeting solid tumors.\n\nThe Waltham, Massachusetts-ba",
"image": "https://s.yimg.com/lo/mysterio/api/4c8e4dc3ba77d2daed8460d7f607914c5b7b0e0dac1fbf9ca6c821d3177429f9/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Finvestorshub_458%2F7a1f2101640b36b807eb9950c7bab566.png"
},
{
"title": "TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript",
"url": "https://seekingalpha.com/article/4942430-tscan-therapeutics-inc-tcrx-discusses-strategic-refocus-on-in-vivo-cell-therapy-for-solid",
"source": "Seeking Alpha",
"date": "2026-09-02 12:14:47",
"summary": "TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript",
"image": "https://images.financialmodelingprep.com/news/tscan-therapeutics-inc-tcrx-discusses-strategic-refocus-on-in-20260902.jpg"
},
{
"title": "TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction",
"url": "https://www.benzinga.com/news/health-care/26/09/61580674/tscan-reorganizes-pipeline-priorities-implements-workforce-reduction",
"source": "Benzinga",
"date": "2026-09-02 11:36:53",
"summary": "TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%.",
"image": "https://images.financialmodelingprep.com/news/tscan-reorganizes-pipeline-priorities-implements-workforce-reduction-20260902.jpg"
},
{
"title": "TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors",
"url": "https://www.globenewswire.com/news-release/2026/09/02/3354974/0/en/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors.html",
"source": "GlobeNewsWire",
"date": "2026-09-02 07:00:00",
"summary": "Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA\u2122 study; 100% (13/13) patients currently being tracked show complete donor chime",
"image": "https://images.financialmodelingprep.com/news/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-20260902.jpg"
},
{
"title": "Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates By Investing.com",
"url": "https://www.investing.com/news/earnings/tscan-therapeutics-earnings-beat-by-003-revenue-fell-short-of-estimates-4854671",
"source": "Investing.com",
"date": "2026-08-12T11:58:19Z",
"summary": "Investing.com - Tscan Therapeutics (NASDAQ: TCRX) reported second quarter EPS of $-0.23, $0.03 better than the analyst estimate of $-0.26. Revenue for the quarter came in at $1.05M versus the consensus estimate of $1.88M.\n\nTscan Therapeutics's stock price closed at $0.78. It is d",
"image": "https://content-media.investing.com/news/LYNXNPEC0L0PD_L.jpg"
},
{
"title": "TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates",
"url": "https://www.zacks.com/stock/news/2973293/tscan-therapeutics-inc-tcrx-reports-q2-loss-misses-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2973293",
"source": "Zacks Investment Research",
"date": "2026-08-12 09:11:04",
"summary": "TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.",
"image": "https://images.financialmodelingprep.com/news/tscan-therapeutics-inc-tcrx-reports-q2-loss-misses-revenue-20260812.jpg"
},
{
"title": "TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update",
"url": "https://www.globenewswire.com/news-release/2026/08/12/3343490/0/en/tscan-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html",
"source": "GlobeNewsWire",
"date": "2026-08-12 07:00:00",
"summary": "First patient dosed in Phase 3 ALLOHA-2\u2122 study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA\u2122 study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2",
"image": "https://images.financialmodelingprep.com/news/tscan-therapeutics-reports-second-quarter-2026-financial-results-and-20260812.jpg"
},
{
"title": "TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2\u2122, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies",
"url": "https://www.globenewswire.com/news-release/2026/07/29/3335095/0/en/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies.html",
"source": "GlobeNewsWire",
"date": "2026-07-29 07:00:00",
"summary": "WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced tha",
"image": "https://images.financialmodelingprep.com/news/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-20260729.jpg"
},
{
"title": "TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference",
"url": "https://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/TScan-Therapeutics-to-Participate-in-the-H-C-Wainwright-4th-Annual-Cell-Therapy-Virtual-Conference.html",
"source": "GlobeNewsWire",
"date": "2026-06-24 07:00:00",
"summary": "WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced tha",
"image": "https://images.financialmodelingprep.com/news/tscan-therapeutics-to-participate-in-the-hc-wainwright-4th-20260624.jpg"
},
{
"title": "TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA\u2122 Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation",
"url": "https://www.globenewswire.com/news-release/2026/06/22/3315162/0/en/TScan-Therapeutics-Announces-Positive-Initial-Data-from-Cohort-C-of-Ongoing-ALLOHA-Phase-1-Study-Evaluating-TSC-101-in-Patients-with-Heme-Malignancies-Undergoing-Allogeneic-Hematop.html",
"source": "GlobeNewswire Inc.",
"date": "2026-06-22T11:00:00Z",
"summary": "TScan Therapeutics reported positive results from Cohort C of its Phase 1 ALLOHA study of TSC-101, a TCR-engineered T cell therapy for hematologic malignancies. 11 of 14 patients achieved complete donor chimerism within three weeks of the first infusion, with all 5 patients asses",
"image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f"
},
{
"title": "Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies",
"url": "https://www.gurufocus.com/news/8898851/cellares-and-tscan-therapeutics-announce-agreement-to-evaluate-automated-manufacturing-of-tsc101-for-patients-with-hematologic-malignancies",
"source": "GuruFocus",
"date": "2026-06-03 10:01:00",
"summary": "Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c",
"image": "https://images.financialmodelingprep.com/news/cellares-and-tscan-therapeutics-announce-agreement-to-evaluate-automated-manufacturing-20260603.png"
},
{
"title": "TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update",
"url": "https://www.globenewswire.com/news-release/2026/05/06/3288637/0/en/TScan-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html",
"source": "GlobeNewswire Inc.",
"date": "2026-05-06T11:00:00Z",
"summary": "TScan Therapeutics reported Q1 2026 financial results with net loss of $28.7 million and revenue of $1.0 million. The company announced multiple clinical milestones including early data from Cohort C of its Phase 1 ALLOHA trial expected in Q2 2026, planned Phase 3 initiation of T",
"image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f"
},
{
"title": "TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference",
"url": "https://www.globenewswire.com/news-release/2026/04/08/3269963/0/en/TScan-Therapeutics-to-Participate-in-the-25th-Annual-Needham-Virtual-Healthcare-Conference.html",
"source": "GlobeNewswire Inc.",
"date": "2026-04-08T11:00:00Z",
"summary": "TScan Therapeutics, a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, announced participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company reported completion of enrollment in Cohort C of i",
"image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f"
},
{
"title": "TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA\u2122 Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03",
"url": "https://www.globenewswire.com/news-release/2026/02/26/3245412/0/en/TScan-Therapeutics-Completes-Enrollment-in-Cohort-C-of-Phase-1-ALLOHA-Trial-and-Announces-FDA-Clearance-of-Investigational-New-Drug-Applications-for-Heme-Candidates-TSC-102-A01-and.html",
"source": "GlobeNewswire Inc.",
"date": "2026-02-26T12:00:00Z",
"summary": "TScan Therapeutics completed enrollment in Cohort C of its Phase 1 ALLOHA\u2122 trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for TSC-102-A01 and TSC-102-A03 candidates targeting CD45 for patients with HLA typ",
"image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f"
},
{
"title": "TScan Therapeutics Announces Positive Updated Data from the ALLOHA\u2122 Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition",
"url": "https://www.globenewswire.com/news-release/2025/12/06/3201100/0/en/TScan-Therapeutics-Announces-Positive-Updated-Data-from-the-ALLOHA-Phase-1-Heme-Trial-at-the-67th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html",
"source": "GlobeNewswire Inc.",
"date": "2025-12-06T22:30:00Z",
"summary": "TScan Therapeutics reported promising results from its Phase 1 trial of TSC-101 for hematologic malignancies, showing improved relapse-free survival and no dose-limiting toxicities in patients undergoing bone marrow transplantation.",
"image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f"
},
{
"title": "Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points",
"url": "https://www.benzinga.com/pressreleases/25/12/n49214477/blood-cancer-therapeutics-reach-critical-commercial-and-clinical-inflection-points?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel",
"source": "Benzinga",
"date": "2025-12-04T17:20:00Z",
"summary": "Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.",
"image": "https://www.benzinga.com/next-assets/images/benzinga-schema-image-default.png"
},
{
"title": "TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025",
"url": "https://www.globenewswire.com/news-release/2025/09/17/3151493/0/en/TScan-Therapeutics-Announces-Upcoming-Oral-and-Poster-Presentations-at-the-American-College-of-Rheumatology-Convergence-2025.html",
"source": "GlobeNewswire Inc.",
"date": "2025-09-17T11:00:00Z",
"summary": "TScan Therapeutics will present two abstracts at the ACR Convergence 2025, highlighting novel discoveries in T cell targets for autoimmune disorders like Ankylosing Spondylitis and Scleroderma using their TargetScan technology.",
"image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f"
},
{
"title": "TScan Therapeutics to Participate in Upcoming Investor Conferences",
"url": "https://www.globenewswire.com/news-release/2025/09/03/3143426/0/en/TScan-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html",
"source": "GlobeNewswire Inc.",
"date": "2025-09-03T11:00:00Z",
"summary": "TScan Therapeutics, a clinical-stage biotech company, announced participation in upcoming investor conferences and provided updates on its T cell receptor (TCR) therapies for cancer treatment, including ongoing clinical trials for hematologic malignancies and solid tumors.",
"image": "https://ml.globenewswire.com/Resource/Download/d8d2632e-0ce4-4ed2-940e-22a1c599d43f"
}
]
Data:
[
{
"symbol": "TCRX",
"date": "2026-11-11",
"epsActual": null,
"epsEstimated": -0.3,
"revenueActual": null,
"revenueEstimated": 1450000,
"lastUpdated": "2026-09-03"
},
{
"symbol": "TCRX",
"date": "2026-08-12",
"epsActual": -0.23,
"epsEstimated": -0.25338,
"revenueActual": 1051000,
"revenueEstimated": 1875000,
"lastUpdated": "2026-09-03"
},
{
"symbol": "TCRX",
"date": "2026-05-06",
"epsActual": -0.22,
"epsEstimated": -0.22,
"revenueActual": 982000,
"revenueEstimated": 2500000,
"lastUpdated": "2026-08-06"
},
{
"symbol": "TCRX",
"date": "2026-03-04",
"epsActual": -0.18,
"epsEstimated": -0.27,
"revenueActual": 2567000,
"revenueEstimated": 2435500,
"lastUpdated": "2026-06-04"
},
{
"symbol": "TCRX",
"date": "2025-11-12",
"epsActual": -0.28,
"epsEstimated": -0.35,
"revenueActual": 2511000,
"revenueEstimated": 1940000,
"lastUpdated": "2026-02-03"
}
]
Data:
{
"borrow": [],
"short_interest": [
{
"symbol": "TCRX",
"file_date": "",
"error": "Symbol not found in FINRA biweekly file",
"days_to_cover": null
}
],
"ftd": {
"symbol": "TCRX",
"periods": [
{
"file_period": "202604b",
"settlement_date": "20260424",
"quantity_fails": 281,
"price": 1.2
},
{
"file_period": "202606a",
"settlement_date": "20260604",
"quantity_fails": 14982,
"price": 0.97
},
{
"file_period": "202607a",
"settlement_date": "20260709",
"quantity_fails": 9702,
"price": 1.26
},
{
"file_period": "202607b",
"settlement_date": "20260717",
"quantity_fails": 16834,
"price": 0.9
},
{
"file_period": "202608a",
"settlement_date": "20260807",
"quantity_fails": 9241,
"price": 0.76
}
],
"trend": "rising",
"trend_description": "FTD quantity increasing \u2014 settlement pressure building, potential squeeze precursor"
}
}
Data:
{
"insider": [
{
"symbol": "TCRX",
"filingDate": "2026-05-22",
"transactionDate": "2026-05-20",
"reportingCik": "0001263508",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 67000,
"reportingName": "BAKER BROS. ADVISORS LP",
"typeOfOwner": "director",
"acquisitionOrDisposition": "A",
"directOrIndirect": "I",
"formType": "4",
"securitiesTransacted": 67000,
"price": 0.9946,
"securityName": "Non- Qualified Stock Option (right to buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526236870/0001193125-26-236870-index.htm"
},
{
"symbol": "TCRX",
"filingDate": "2026-05-22",
"transactionDate": "2026-05-20",
"reportingCik": "0001996804",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 67000,
"reportingName": "Woods Keith",
"typeOfOwner": "director",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 67000,
"price": 0.9946,
"securityName": "Stock Option (Right to Buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526236855/0001193125-26-236855-index.htm"
},
{
"symbol": "TCRX",
"filingDate": "2026-05-22",
"transactionDate": "2026-05-20",
"reportingCik": "0001640861",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 67000,
"reportingName": "Nicholson Garry A",
"typeOfOwner": "director",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 67000,
"price": 0.9946,
"securityName": "Stock Option (Right to Buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526236854/0001193125-26-236854-index.htm"
},
{
"symbol": "TCRX",
"filingDate": "2026-05-22",
"transactionDate": "2026-05-20",
"reportingCik": "0001860326",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 67000,
"reportingName": "Gruia Gabriela",
"typeOfOwner": "director",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 67000,
"price": 0.9946,
"securityName": "Stock Option (Right to Buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526236848/0001193125-26-236848-index.htm"
},
{
"symbol": "TCRX",
"filingDate": "2026-05-22",
"transactionDate": "2026-05-20",
"reportingCik": "0001617541",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 67000,
"reportingName": "Dorton Katina",
"typeOfOwner": "director",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 67000,
"price": 0.9946,
"securityName": "Stock Option (Right to Buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526236844/0001193125-26-236844-index.htm"
},
{
"symbol": "TCRX",
"filingDate": "2026-05-22",
"transactionDate": "2026-05-20",
"reportingCik": "0001647647",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 67000,
"reportingName": "Klencke Barbara",
"typeOfOwner": "director",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 67000,
"price": 0.9946,
"securityName": "Stock Option (Right to Buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526236841/0001193125-26-236841-index.htm"
},
{
"symbol": "TCRX",
"filingDate": "2026-01-22",
"transactionDate": "2026-01-20",
"reportingCik": "0001451805",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 350000,
"reportingName": "Amello Jason",
"typeOfOwner": "officer: Chief Financial Officer",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 350000,
"price": 1.12,
"securityName": "Stock Option (Right to Buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526019729/0001193125-26-019729-index.htm"
},
{
"symbol": "TCRX",
"filingDate": "2026-01-22",
"transactionDate": "2026-01-20",
"reportingCik": "0001738082",
"companyCik": "0001783328",
"transactionType": "A-Award",
"securitiesOwned": 1165000,
"reportingName": "MacBeath Gavin",
"typeOfOwner": "director, officer: Chief Executive Officer",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 1165000,
"price": 1.12,
"securityName": "Stock Option (Right to Buy)",
"url": "https://www.sec.gov/Archives/edgar/data/1783328/000119312526019723/0001193125-26-019723-index.htm"
}
],
"congress": [
"status",
"endpoint",
"provided",
"message",
"status",
"endpoint",
"provided",
"message"
],
"dark_pool": [
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:15:37.245000Z",
"size": 5100.0,
"price": 0.3738,
"premium": 1906.38,
"volume": 5100.0,
"trade_code": " "
},
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:15:37.269000Z",
"size": 3400.0,
"price": 0.3794,
"premium": 1289.96,
"volume": 3400.0,
"trade_code": " "
},
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:15:37.252000Z",
"size": 3300.0,
"price": 0.3738,
"premium": 1233.54,
"volume": 3300.0,
"trade_code": " "
},
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:15:37.257000Z",
"size": 2200.0,
"price": 0.3738,
"premium": 822.36,
"volume": 2200.0,
"trade_code": " "
},
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:24:07.859000Z",
"size": 2000.0,
"price": 0.3751,
"premium": 750.1999999999999,
"volume": 2000.0,
"trade_code": " "
},
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:19:18.425000Z",
"size": 1900.0,
"price": 0.3753,
"premium": 713.07,
"volume": 1900.0,
"trade_code": " "
},
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:15:37.280000Z",
"size": 1674.0,
"price": 0.3752,
"premium": 628.0848,
"volume": 1674.0,
"trade_code": " "
},
{
"ticker": "TCRX",
"executed_at": "2026-09-03T18:15:37.244000Z",
"size": 1400.0,
"price": 0.3738,
"premium": 523.32,
"volume": 1400.0,
"trade_code": " "
}
],
"ats": {
"symbol": "TCRX",
"date": "20260902",
"ats_volume": 0,
"total_volume": 5971886,
"ats_ratio": 0.0,
"ats_pct": 0.0,
"signal": "Low",
"history": [
{
"date": "20260902",
"ats_ratio": 0.0
},
{
"date": "20260901",
"ats_ratio": 0.0
},
{
"date": "20260831",
"ats_ratio": 0.0
},
{
"date": "20260828",
"ats_ratio": 0.0
},
{
"date": "20260827",
"ats_ratio": 0.0
}
]
},
"polygon_dp": {
"ticker": "TCRX",
"days": [
{
"date": "2026-09-03",
"close": 0.3752,
"vwap": 0.37,
"volume": 2432225,
"vwap_discount_pct": -0.72
},
{
"date": "2026-09-02",
"close": 0.3811,
"vwap": 0.41,
"volume": 8517352,
"vwap_discount_pct": 8.13
},
{
"date": "2026-09-01",
"close": 0.6663,
"vwap": 0.67,
"volume": 820279,
"vwap_discount_pct": 1.01
},
{
"date": "2026-08-31",
"close": 0.7297,
"vwap": 0.74,
"volume": 330387,
"vwap_discount_pct": 1.18
},
{
"date": "2026-08-28",
"close": 0.7535,
"vwap": 0.75,
"volume": 150791,
"vwap_discount_pct": -0.21
}
],
"avg_vwap_discount_pct": 1.88,
"signal": "Accumulation"
},
"options_flow": [],
"net_premium": {
"ticker": "TCRX",
"net_call_premium": null,
"net_put_premium": null,
"call_premium": null,
"put_premium": null,
"bullish_premium": null,
"bearish_premium": null,
"put_call_ratio": null,
"iv_rank": null,
"implied_move_perc": null,
"gex_ratio": null,
"gex_net_change": null
},
"hot_chains": [],
"gamma_profile": {
"ticker": "TCRX"
},
"oi_changes": {},
"opds": {
"opds": 0.0,
"D": 38.4,
"P": -76.8,
"O": 0,
"C": 0.0,
"signal": "NEUTRAL",
"direction": "flat",
"coverage": 0.0,
"ranked": false,
"components": {
"M": -81.5,
"T": -100.0,
"RS": -100.0,
"V": -16.3,
"F": null,
"OI": null,
"S": null,
"IV": null,
"B": null,
"Liquidity": null,
"OpeningConfidence": null,
"FlowAgreement": null,
"StrikeBreadth": null
},
"drivers": [
"- trend -100",
"- relative strength -100",
"- momentum -81"
]
}
}
Data:
{
"vix": 14.92,
"sp500": 7686.14,
"fed_funds": 3.63,
"yield_curve_10y2y": 0.41,
"hy_spread": 2.6,
"treasury": {
"date": "2026-09-01",
"month1": 3.85,
"month2": 3.89,
"month3": 3.92,
"month6": 4,
"year1": 4.18,
"year2": 4.39,
"year3": 4.46,
"year5": 4.55,
"year7": 4.66,
"year10": 4.79,
"year20": 5.27,
"year30": 5.27
},
"events": [
{
"title": "Average Hourly Earnings m/m",
"currency": "USD",
"date": "2026-09-04",
"time_utc": "12:30",
"impact": "High",
"forecast": "0.3%",
"previous": "0.1%",
"actual": null,
"minutes_until": 1085
},
{
"title": "Non-Farm Employment Change",
"currency": "USD",
"date": "2026-09-04",
"time_utc": "12:30",
"impact": "High",
"forecast": "55K",
"previous": "-23K",
"actual": null,
"minutes_until": 1085
},
{
"title": "Unemployment Rate",
"currency": "USD",
"date": "2026-09-04",
"time_utc": "12:30",
"impact": "High",
"forecast": "4.1%",
"previous": "4.1%",
"actual": null,
"minutes_until": 1085
}
]
}
Data:
{
"days": 106,
"patterns": [
{
"name": "VWAP Touch",
"count": 106,
"pct": 100
},
{
"name": "9 EMA Touch",
"count": 106,
"pct": 100
},
{
"name": "21 EMA Touch",
"count": 106,
"pct": 100
},
{
"name": "Woodie Pivot Touch",
"count": 100,
"pct": 94
},
{
"name": "ORB Breakout",
"count": 99,
"pct": 93
},
{
"name": "PDH/PDL Touch",
"count": 87,
"pct": 82
},
{
"name": "Gap Fill",
"count": 74,
"pct": 70
},
{
"name": "Open Retracement",
"count": 69,
"pct": 65
},
{
"name": "Power Hour",
"count": 44,
"pct": 42
},
{
"name": "High Vol Open",
"count": 37,
"pct": 35
},
{
"name": "Darvas Box",
"count": 35,
"pct": 33
}
]
}